Personalising Radiotherapy Using MRI and Tumour Samples in Prostate and Breast Cancer
Studies MRI scans and tumour biopsies to tailor radiotherapy for prostate or breast cancer.
Plain-language title generated from the registry record
Registry title: Personalization of External Beam Radiation Therapy in Localised Tumours
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early, localised prostate cancer or breast cancer who will have active treatment, including radiotherapy. MRI scans and, for some, a biopsy before radiotherapy are part of the study.
- Age
- Over 18 years
- Sex
- All sexes in the entry list, but male sex is an exclusion for breast patients
- Disease stage
- Breast: one tumour (unifocal infiltrating ductal carcinoma, non-special histotype), clinical stage T1-T2, N0. Prostate: no nodule involvement or metastasis (cN1 and/or cM1).
- Earlier treatment
- Breast: no neoadjuvant therapy and no previous radiotherapy to the chest. Prostate: active treatment expected (cryoablation, surgery or radiotherapy).
Main reasons for not taking part
- Contraindications to MRI
- Spread to nodes or distant metastases
- Earlier invasive cancer, unless disease-free for at least 3 years (prostate)
- Breast: bilateral breast cancer, high-risk mutation carrier, or autoimmune connective tissue disease
- Mental disorders that prevent valid informed consent
Read by machine on 12 November 2026.
Where in Italy
- European Institute of OncologyMilan, ItalyContact: Giulia MarvasoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT07047495
- Record updated
- 2 July 2025
- Original description
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).Read full original descriptionShow less
MINIONS - Patient-specific Microstructural and radIobiological Model for persoNalised External Beam radiatION Therapy in Localised tumourS
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
Within the prospective study, biological specimens from patients undergoing in-room biopsy before RT, will be collected. Histological evaluation and cell culture (and organoid preparation) will be conducted, and samples/organoids will be irradiated with RT for biological validation.
Inclusion: Unifocal infiltrating ductal breast carcinoma, non-special histotype; clinical stage T1-T2,N0; No contraindications to MRI, or metal joint prostheses from knee to shoulder included, or femoral stent; Patients aged >18 years; Good general condition (ECOG 0-2); Expected active treatment (crioablation or surgery or radiotherapy ).
Exclusion: Neoadjuvant therapy; previous radiotherapy to the chest; No previous thoracic radiotherapy; Exclusion criteria for prostate patients:; Nodule involvement and metastasis (cN1 and/or cM1); Concomitant inflammation of the intestine; Significant systemic diseases or ongoing oral anticoagulant therapy; Non-compliance of dose constraints in the treatment plan; Previous invasive cancer, unless the patient has had no disease for at least 3 years; Mental disorders that cannot ensure valid informed consent; Bilateral breast cancer; autoimmune connective tissue diseases; Mental disorders that cannot ensure valid informed consent; Histology other than non-special histotype and non-epithelial tumors (sarcoma, lymphoma); Male sex; High-risk mutation carrier patients; synchronous distant metastases.